March 2024 – Valerie Gharagouzloo, co-Founder at Imaginostics, is set to present at the esteemed Hello Tomorrow Global Summit in Paris, France, on March 21st-22nd, showcasing the groundbreaking QUTE-CE MRI technology that is poised to transform diagnostic imaging.

Imaginostics, a finalist in the renowned Hello Tomorrow Global Challenge, was selected from over 4,500 applicants worldwide, a testament to the innovative approach and potential impact of their QUTE-CE MRI technology. The company, under Gharagouzloo’s guidance, specializes in non-invasive, quantitative imaging technology designed to enhance vascular structure and function analysis throughout the body, with significant implications for neurology, cardiology, and oncology.

The Hello Tomorrow Global Summit is an incubator for deep tech advancements, addressing some of the most pressing global challenges through technology and innovation. This year’s summit will not only spotlight the finalists but also serve as a convergence point for industry leaders, investors, and innovators.

“Being recognized as a finalist is a monumental achievement for us,” said Gharagouzloo. “It’s a validation of our hard work and the potential of QUTE-CE MRI to revolutionize how we approach diagnostic imaging for a myriad of diseases. We’re excited to share our technology with the global community and explore partnerships that could further our impact.”

Imaginostics stands at the forefront of the Digital Health & Medical Devices category, promising a future where precise, non-invasive imaging techniques become a cornerstone of personalized medicine. The technology’s precision and its ability to provide 10X better vascular images while eliminating toxic gadolinium contrast underscore its potential to become a game-changer in the field.

The Hello Tomorrow Global Summit offers an unparalleled platform for emerging technologies, highlighting the importance of innovation in tackling health and environmental challenges. For Imaginostics, it represents an opportunity to gain visibility, attract investment, and forge partnerships that could accelerate the adoption of QUTE-CE MRI in healthcare systems worldwide.

As the summit approaches, the Imaginostics team is gearing up for what could be a pivotal moment in the company’s journey. A win at the Hello Tomorrow challenge would not only bring substantial equity-free funding but also access to a tailored coaching program and invaluable connections within the industry.

For more information about Imaginostics and the revolutionary QUTE-CE MRI technology, visit our website or follow us on social media for live updates from the Hello Tomorrow Global Summit.

Dr. Codi Gharagouzloo, an MRI physicist, and his wife, New York attorney Valerie Gharagouzloo, created Imaginostics to advance medical breakthroughs for uncurable diseases with their imaging biomarkers.

Imaginostics, a promising startup company founded in 2018, is bringing to market a revolutionary longevity technology for early detection of diseases decades in advance through MRIs. The company’s technology uses a new way to acquire data from existing MRI scanners and hardware, improving MRIs by 10x and enabling new physiological measurements that describe the cellular vascular environment. This represents a potential breakthrough for the early detection of many age-related diseases, and in particular Alzheimer’s disease and related dementia.

Imaginostics was founded by Dr. Codi and Valerie Gharagouzloo, a French American couple who met in Valerie’s native France in 2007, were married in 2010, and have two children. Dr. Gharagouzloo invented and developed the breakthrough quantitative imaging technology during his Ph.D. in bioengineering at Northeastern University and postdoctoral research fellowship at Harvard-affiliated Massachusetts General Hospital in Boston. Valerie inspired Codi to launch his startup to bring his extraordinary tech from bench to bedside.

“At the heart of the technology is quantum physics, where we overcome the qualitative limitations of magnetic susceptibility using ultra-short measurement times 1,000x earlier than standard MRIs. As a bonus, the tech is compatible with an iron supplement for contrast and doesn’t require toxic gadolinium,” Codi said. “From there, we can quantify microvascular density, function, and leakage.”

“Alzheimer’s disease is like a black box from the day you’re born until the day you develop symptoms,” Codi added. “We’ve known that blood vessels are abnormal, but current technologies can’t quantify it at the individual level.

“There are lots of exciting drugs in development that could not only cure Alzheimer’s but extend a healthy lifespan. We are just one piece of the puzzle: quantitative imaging biomarkers of aging for fast and high-throughput testing.”

In 2022, the company raised $1.35 million in grants, including nearly $1 million from an NIH-NIA SBIR Grant for Clinical Validation for Novel MRI Biomarkers in screening and quantification of mild cognitive impairment, boosted by an investment by the Alzheimer’s Drug Discovery Foundation of $725,000. Imaginostics is fundraising another $2.2 million to consolidate the team at Lake Nona Medical City in Orlando and launch its first phase of commercialization for accelerating drug development. The company expects first sales to pharmaceutical companies in 2024, and partners with clinical research organizations.

“We are still living in the stone age with current MRIs and there haven’t been any precision advancements for decades,” Codi said. “For the first time, Imaginostics can visualize the vasculature throughout the whole body, assay health and disease, stratify patient populations, and assess drug efficacy at the individual level.”

Imaginostics is creating the next generation of precision medicine diagnostic tools for clinicians and drug developers to transform personalized healthcare, accelerate drug development and fight aging.

“Preventive medical care is better than curative care. We want to transform lives by empowering people to take control of their own health and well-being,” Valerie said.

For more information, visit https://imaginostics.com